Cocaine Abuse, Cocaine Dependence, Opiate Dependence, Alcohol Dependence, Substance Abuse
Conditions
Keywords
Substance Abuse, Treatment, Eligibility
Brief summary
The overarching goal of this project is to have a consolidated consent and evaluation procedure that will lead potential subjects to the most appropriate clinical trial or human laboratory study (and its consent process) for their presenting concerns or interests. A second purpose is to have a consolidated intake data base on which secondary analyses can be conducted.
Detailed description
Approximately 1500 candidates per year will respond to advertisements and will complete preliminary telephone screening without identifiers. Appropriate candidates will be given appointment times and on arrival will undergo the consent process for evaluation. A complete medical, social, psychiatric, and drug use history will be obtained. Subjects fulfilling general health inclusion requirements will then be offered an appropriate study for which the specific consent will be obtained. The evaluation period will be no more than one day with all results evaluated within the two following days. Acceptable candidates will then be invited to complete the study specific consent.
Interventions
DRUGmodafinil
400 mg daily
DRUGd-amphetamine
60mg daily
DRUGL-Dopa
800/200mg daily
DRUGNaltrexone
50mg daily
Sponsors
National Institute on Drug Abuse (NIDA)
The University of Texas Health Science Center, Houston
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Willing and able to participate in 3- to 6-month treatment program. * At least 18 years of age. * Seeking treatment for substances of abuse including (cocaine, opiates, and alcohol). * Generally physically healthy.
Exclusion criteria
* Pregnant or breastfeeding. * Mandated by the courts/parole officers to attend treatment. * Not seeking treatment for substances of abuse. * Plans to move from the Houston area within the 3- to 6-month treatment period. * Seeking treatment for a substance for which the Treatment Research Clinic (TRC) has no current trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine Toxicology | 6 weeks to 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Demographics | 6 weeks to 24 weeks |
Countries
United States
Contacts
Primary ContactJessica Vincent, BS
Outcome results
None listed